Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), caught up with Proactive's Andrew Scott following the release of the skin-health specialist's interim results.
She says they remain on track with the development of their three flagship programmes - in particular the upcoming first human study for the cosmetic application of the compound which is planned for the third quarter of this year.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>